Search research articles
Contact Us
Filters
Showing results (1-10 of 147) with videos related to
Page
of 15
Sort By:
European Urology Oncology
|
January 27, 2023
Re: Bo Dai, Sheng Zhang, Fan-Ning Wan, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer : A Phase 2 Randomized Controlled Trial. Eur Urol Oncol 2022;5:519-25
Francesco Montorsi, Francesco Barletta, Giorgio Gandaglia
European Urology Open Science
|
August 31, 2022
Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course
Giorgio Gandaglia, Francesco Barletta, Francesco Montorsi, et al.
European Urology
|
March 27, 2025
Re: Andreas Josefsson, Marianne Månsson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. Eur Urol 2024;86:223-9
Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, et al.
European Urology Oncology
|
February 28, 2024
Re: Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007
Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, et al.
European Urology
|
October 13, 2023
Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2022;83:521-33
Giorgio Gandaglia, Francesco Barletta, Alberto Briganti, et al.
European Urology Focus
|
July 16, 2023
Re: Ragheed Saoud, Varat Woranisarakul, Gladell P. Paner, et al. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.002
Giorgio Gandaglia, Francesco Barletta, Alberto Briganti, et al.
European Urology
|
August 12, 2025
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial
Francesco Montorsi, Francesco Barletta, Giorgio Gandaglia, et al.
European Urology Oncology
|
February 8, 2025
Re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60
Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, et al.
European Urology
|
September 27, 2024
Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer
Giorgio Gandaglia, Francesco Barletta, Alberto Briganti, et al.
European Urology
|
February 10, 2026
Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al.
Page
of 15
Search research articles
Search
Showing results (1-10 of 147) with videos related to
Sort By:
Page
of 15
European Urology Oncology
|
January 27, 2023
Re: Bo Dai, Sheng Zhang, Fan-Ning Wan, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer : A Phase 2 Randomized Controlled Trial. Eur Urol Oncol 2022;5:519-25
Francesco Montorsi, Francesco Barletta, Giorgio Gandaglia
European Urology Open Science
|
August 31, 2022
Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course
Giorgio Gandaglia, Francesco Barletta, Francesco Montorsi, et al.
European Urology
|
March 27, 2025
Re: Andreas Josefsson, Marianne Månsson, Kimia Kohestani, et al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. Eur Urol 2024;86:223-9
Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, et al.
European Urology Oncology
|
February 28, 2024
Re: Ost P, Siva S, Brabrand S, et al. PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007
Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, et al.
European Urology
|
October 13, 2023
Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2022;83:521-33
Giorgio Gandaglia, Francesco Barletta, Alberto Briganti, et al.
European Urology Focus
|
July 16, 2023
Re: Ragheed Saoud, Varat Woranisarakul, Gladell P. Paner, et al. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.002
Giorgio Gandaglia, Francesco Barletta, Alberto Briganti, et al.
European Urology
|
August 12, 2025
Re: Effect of NeuroSAFE-guided RARP Versus Standard RARP on Erectile Function and Urinary Continence in Patients with Localised Prostate Cancer (NeuroSAFE PROOF): A Multicentre, Patient-blinded, Randomised, Controlled Phase 3 Trial
Francesco Montorsi, Francesco Barletta, Giorgio Gandaglia, et al.
European Urology Oncology
|
February 8, 2025
Re: Bertrand F. Tombal, Francisco Gomez-Veiga, Alvaro Gomez-Ferrer, et al. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 2024;7:1051-60
Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, et al.
European Urology
|
September 27, 2024
Re: Long-term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-Risk Prostate Cancer
Giorgio Gandaglia, Francesco Barletta, Alberto Briganti, et al.
European Urology
|
February 10, 2026
Re: Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
Francesco Barletta, Chiara Mercinelli, Francesco Montorsi, et al.
Page
of 15